Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients.

The resistance of parathyroid cells to 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in uremic hyperparathyroidism is thought to be caused, in part, by a 1,25(OH)2D3 receptor (VDR) deficiency in the parathyroids. However, results of biochemical studies addressing VDR numbers in the parathyroids are controversial. Several studies have found VDR content to be decreased in the parathyroids of uremic patients and animals, while others have found no such decrease in the parathyroids of uremic animals. To clarify the role of VDR, we investigated VDR distribution in surgically-excised parathyroids obtained from chronic dialysis patients by immunohistochemistry. We classified the parathyroids as exhibiting nodular or diffuse hyperplasia. Our studies demonstrated a lower density of VDR in the parathyroids showing nodular hyperplasia than in those showing diffuse hyperplasia. Even in the parathyroids showing diffuse hyperplasia, nodule-forming areas were present; these areas were virtually negative for VDR staining. A significant negative correlation was found between VDR density and the weight of the parathyroids. These findings indicate that the conflicting results of biochemical studies may be caused by the heterogeneous distribution of VDR; the decreased VDR density in parathyroids may contribute to the progression of secondary hyperparathyroidism and to the proliferation of parathyroid cells that is seen in uremia.

[1]  E. Slatopolsky,et al.  A new sensitive homologous radioimmunoassay for amino‐terminal parathyroid hormone in the rat , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  L. Grimelius,et al.  DNA ploidy pattern of parathyroid parenchymal cells in renal secondary hyperparathyroidism with relapse. , 1991, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[3]  E. Ritz,et al.  No decrease of 1,25(OH)2D3 receptors and duodenal calbindin‐D9k in uraemic rats , 1991, European journal of clinical investigation.

[4]  E. Ogata,et al.  Regulation of parathyroid hormone synthesis in chronic renal failure in rats. , 1991, Kidney international.

[5]  J. Silver,et al.  Regulation of parathyroid cell gene expression in experimental uremia. , 1990, Journal of the American Society of Nephrology : JASN.

[6]  R. Dunlay,et al.  Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis. , 1989, Kidney international.

[7]  J. Rastad,et al.  Surgical findings and results of subtotal and total parathyroidectomy in hypercalcemic patients with uremic hyperparathyroidism. , 1989, Acta chirurgica Scandinavica.

[8]  G. Hendy,et al.  Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. , 1989, Endocrinology.

[9]  J. Rastad,et al.  Parathyroid histology and cytology with monoclonal antibodies recognizing a calcium sensor of parathyroid cells. , 1989, The American journal of pathology.

[10]  J. Delmez,et al.  Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium. , 1989, The Journal of clinical investigation.

[11]  E. Ritz,et al.  1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. , 1989, Kidney international.

[12]  H. Kronenberg,et al.  5'-flanking region of the parathyroid hormone gene mediates negative regulation by 1,25-(OH)2 vitamin D3. , 1988, The Journal of biological chemistry.

[13]  E. Ritz,et al.  Diminished parathyroid 1,25(OH)2D3 receptors in experimental uremia. , 1987, Kidney international.

[14]  J. Russell,et al.  Suppression by 1,25(OH)2D3 of transcription of the pre-proparathyroid hormone gene. , 1986, Endocrinology.

[15]  J. Silver,et al.  Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. , 1986, The Journal of clinical investigation.

[16]  J. Russell,et al.  1,25-Dihydroxyvitamin D3 suppresses parathyroid hormone secretion from bovine parathyroid cells in tissue culture. , 1985, Endocrinology.

[17]  M. Krause,et al.  Pathologic study of parathyroid glands in tertiary hyperparathyroidism. , 1985, Human pathology.

[18]  H. Takagi,et al.  [Histopathological study of the parathyroid gland in renal hyperparathyroidism]. , 1985, Nihon Geka Gakkai zasshi.

[19]  H. Harter,et al.  Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. , 1984, The Journal of clinical investigation.

[20]  J. Pike.  Monoclonal antibodies to chick intestinal receptors for 1,25-dihydroxyvitamin D3. Interaction and effects of binding on receptor function. , 1984, The Journal of biological chemistry.

[21]  H. Takagi,et al.  Polymorphism of parathyroid glands in patients with chronic renal failure and secondary hyperparathyroidism. , 1983, Endocrinologia japonica.

[22]  H. Kronenberg,et al.  Parathyroid hormone messenger ribonucleic acid: effects of calcium on cellular regulation in vitro. , 1983, Endocrinology.

[23]  M. Brandi,et al.  Progression of uremic hyperparathyroidism involves allelic loss on chromosome 11. , 1993, The Journal of clinical endocrinology and metabolism.

[24]  A. Dusso,et al.  1,25-(OH)2D receptors are decreased in parathyroid glands from chronically uremic dogs. , 1989, Kidney international.

[25]  G. Åkerström,et al.  Parathyroid pathology in hyperparathyroidism secondary to chronic renal failure. , 1984, Scandinavian journal of urology and nephrology.

[26]  G. Åkerström,et al.  Histological changes in parathyroid glands in subclinical and clinical renal disease. An autopsy investigation. , 1984, Scandinavian journal of urology and nephrology.